Global women's health therapeutics market to reach value of $22.7 billion by 2017
There is room for improvement in the female health disorders market, and this is fuelling pharmaceutical companies to invest in R&D programs. Increased focus is being shown in therapy areas such as menopause, female sexual dysfunction and infertility, as large target markets and unsatisfactory existing treatments make patients a willing target for new treatments.
The ageing population is driving the menopause therapeutics market, as menopausal symptoms often emerge after the age of 50, with indications such as hot flashes affecting up to 85% of menopausal women. As the population grows older, the number of postmenopausal women will increase.
The menopause therapeutics market is currently dominated by hormone therapies with highly questionable safety profiles. Patients as well as physicians are often reluctant to try hormone therapy as the first line treatment for menopausal symptoms and osteoporosis, as a result of studies such as the WHI Memory Study (WHIMS), the Estrogen Replacement and Atherosclerosis (ERA) study, and the Million Women Study, which have all raised concerns over the safety profile of hormone treatment (HT). Results suggested that hormone treatment (HT) was associated with an increased risk of breast cancer, venous thromboembolism and stroke. The availability of alternative options such as lifestyle and diet changes, exercise and home remedies has also damaged the hormone therapy market, as despite the severity of postmenopausal symptoms, a majority of postmenopausal women tend to opt for home remedies and lifestyle changes rather than using hormone therapy.
Aprela is a progesterone-free treatment for menopausal symptoms which combines conjugated estrogens and bazedoxifene. The drug is currently under review by the US FDA for approval, and is predicted to restore the HT market with peak sales of approximately $1 billion after its expected approval next year. Aprela has shown favorable results in initial studies in comparison to other HT therapeutics, with studies suggesting that Aprela may pose fewer risks and milder side effects than Prempro and Premarin, and no evidence of breast tenderness and pain or increased breast cancer rates as compared to Evista. Other studies revealed that Aprela recipients experienced better sleep and diminished hot flashes compared to women who were treated with a placebo. The drug may therefore provide a better line of treatment for postmenopausal women. Once approved, the treatment is expected to compete strongly with medication currently on offer, significantly altering the menopause market dynamics.
Progression is also being made in the treatment of related menopausal conditions. The female sexual dysfunction therapeutics market currently does not have any FDA approved drugs that are comparable to Viagra for males, but there are many promising molecules in the late stage development phase, most of which have demonstrated high safety and efficacy profiles in clinical trials. If these new therapies can cater to the significant unmet need associated with current treatment options for female sexual dysfunction, they can command a price premium and drive the womens therapy market.
Steps are also being made in the postmenopausal osteoporosis market, with Amgen Inc recently launching first-in-class drug Prolia, and Mercks cathepsin K inhibitor Odanacatib (MK-0822) also showing promising results.
In 2011, the womens health therapeutics market was estimated to be worth $18.8 billion. We forecast the market to grow at a Compound Annual Growth Rate (CAGR) of 2.7% between 2011 and 2018, to record a sales value of $22.7 billion in 2018. The patent expiries of blockbusters such as Evista, the Premarin family, Forteo, Mirena, Boniva, Actonel, Gonal-F and others during the forecast period are expected to slow down the market growth for the womens health therapeutics market. The launch of novel molecules like Elagolix and Odanacatib in the late stage pipeline will drive the market in the forecast period.
The womens health therapeutics market R&D pipeline shows promising molecules. The current treatment options for womens disorders are limited due to lack of safety. The unmet need in the womens disorders market is attracting the pharmaceutical companies to invest in R&D programs. Increased focus is seen on therapy areas such as menopause, female sexual dysfunction and infertility.
This report provides insights into the womens health therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts. It provides an in-depth analysis of the major diseases, and includes coverage of menopause, postmenopausal osteoporosis, endometriosis, infertility, and female contraceptives. The report provides in-depth analysis of the drivers and barriers that affect the global womens health market, and analyzes the markets for womens health disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. The report also analyzes the womens health therapeutics market in India, China and Australia. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global market.
- Annualized market data for the womens health disorders market from 2003 to 2011, with forecasts to 2018.
- Analysis of the leading therapeutic segments, including menopause, postmenopausal osteoporosis, endometriosis, infertility, and the female contraceptives market.
- Analysis of the womens health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the womens health therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, F. Hoffman-La Roche Ltd., Merck, Bayer and Warner Chilcott Plc.
- Key M&A activities and licensing agreements that took place in the years 2010 to 2012 in the womens health therapeutics market.
Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Develop market entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.